STOCK TITAN

Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Negative)
Tags

Nutriband (NASDAQ:NTRB) has received full patent issuance from the Chinese National Intellectual Property Administrant (CNIPA) for its 'Abuse and Misuse Deterrent Transdermal System.' The patent (No: ZL 202211158031) supports the company's AVERSA™ technology, developed by 4p Therapeutics, which incorporates taste aversion to prevent abuse of opioid-based transdermal patches. This follows CNIPA's notice of allowance issued in September 2024.

Nutriband (NASDAQ:NTRB) ha ricevuto l'emissione completa del brevetto dalla National Intellectual Property Administrant Cinese (CNIPA) per il suo 'Sistema Transdermico di Deterrente contro l'Abuso e l'Uso Improprio.' Il brevetto (No: ZL 202211158031) supporta la tecnologia AVERSA™, sviluppata da 4p Therapeutics, che incorpora l'avversione al gusto per prevenire l'abuso di cerotti transdermici a base di oppioidi. Questo segue la comunicazione di autorizzazione della CNIPA emessa nel settembre 2024.

Nutriband (NASDAQ:NTRB) ha recibido la concesión completa de la patente por parte de la Administración Nacional de Propiedad Intelectual de China (CNIPA) para su 'Sistema Transdérmico de Disuasión contra el Abuso y el Uso Indebido.' La patente (No: ZL 202211158031) respalda la tecnología AVERSA™, desarrollada por 4p Therapeutics, que incorpora una aversión al gusto para prevenir el abuso de parches transdérmicos a base de opioides. Esto sigue a la notificación de aprobación de la CNIPA emitida en septiembre de 2024.

뉴트리밴드 (NASDAQ:NTRB)는 '중국 국가 지식 재산권 관리국 (CNIPA)'로부터 '남용 및 오용 억제 피부 패치 시스템'에 대한 전체 특허 승인을 받았습니다. 특허(번호: ZL 202211158031)는 4p Therapeutics가 개발한 AVERSA™ 기술을 지원하며, 이는 맛 기피를 통합하여 오피오이드 계열의 경피 패치 남용을 방지합니다. 이는 2023년 9월에 발행된 CNIPA의 허가 통지에 따른 것입니다.

Nutriband (NASDAQ:NTRB) a reçu une concession complète de brevet de la Administration nationale de la propriété intellectuelle de Chine (CNIPA) pour son 'Système transdermique de dissuasion contre l'abus et l'utilisation abusive.' Le brevet (No : ZL 202211158031) soutient la technologie AVERSA™, développée par 4p Therapeutics, qui intègre une aversion au goût pour prévenir l'abus de patchs transdermiques à base d'opioïdes. Cela fait suite à l'avis d'autorisation de la CNIPA émis en septembre 2024.

Nutriband (NASDAQ:NTRB) hat eine vollständige Patenterteilung von der Chinesischen Nationalen Behörde für geistiges Eigentum (CNIPA) für sein 'Transdermales System zur Abschreckung von Missbrauch und Fehlgebrauch' erhalten. Das Patent (Nr.: ZL 202211158031) unterstützt die AVERSA™-Technologie, die von 4p Therapeutics entwickelt wurde und eine Geschmacksvermeidung integriert, um den Missbrauch von opioidhaltigen Transdermalpflastern zu verhindern. Dies folgt der Genehmigungsmitteilung der CNIPA, die im September 2024 erteilt wurde.

Positive
  • Secured full patent protection in China for AVERSA™ technology
  • Strengthens intellectual property portfolio in major market
  • Expands international patent coverage for abuse-deterrent technology
Negative
  • None.

Insights

The issuance of this Chinese patent significantly strengthens Nutriband's intellectual property portfolio in a major pharmaceutical market. The AVERSA technology's taste aversion approach for deterring opioid patch abuse represents a novel solution in the transdermal drug delivery space. Patent protection in China is particularly valuable given the country's large pharmaceutical market and manufacturing capabilities.

The timing is strategic, as China has been expanding its pharmaceutical sector and increasing regulations around opioid medications. This patent could position Nutriband for potential licensing deals or partnerships with Chinese pharmaceutical companies. The 20-year protection period from the filing date provides substantial runway for commercialization opportunities in the Chinese market.

ORLANDO, FL / ACCESSWIRE / October 31, 2024 / Nutriband (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced that theChinese National Intellectual Property Administrant (CNIPA) has fully issued its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the Company's lead technology AVERSA™.

The patent underpins 4p Therapeutics' abuse deterrent transdermal system, AVERSA, which uses taste aversion to address the primary routes of abuse for opioid based transdermal patches. The patent number reflects the issuance of Patent No: ZL 202211158031.

The CNIPA issued a prior notice of allowance in September 2024.

About AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, and Australia.

About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.

Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form 10-K for the year ended January 31, 2024, filed May 1, 2024, the Forms 10-Q's filed subsequent to the Form 10-K in 2024, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Contact Information:
Investor Relations
RedChip Companies, Inc.
Dave Gentry
Email: NTRB@Redchip.com
Phone: 1-800-RED-CHIP (733-2447)
or 407-644-4256
Address:
431 E Horatio Ave, Suite #100
Maitland, FL 32751

Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com

SOURCE: Nutriband, Inc.



View the original press release on accesswire.com

FAQ

What patent did Nutriband (NTRB) receive in China?

Nutriband received a patent titled 'Abuse and Misuse Deterrent Transdermal System' (Patent No: ZL 202211158031) from the Chinese National Intellectual Property Administrant in October 2024.

What is the purpose of Nutriband's (NTRB) AVERSA technology?

AVERSA technology uses taste aversion to prevent the abuse of opioid-based transdermal patches by addressing primary routes of abuse.

When did CNIPA issue the notice of allowance for Nutriband's (NTRB) patent?

The Chinese National Intellectual Property Administrant (CNIPA) issued the notice of allowance in September 2024.

Nutriband Inc.

NASDAQ:NTRB

NTRB Rankings

NTRB Latest News

NTRB Stock Data

52.64M
3.29M
54.05%
2.38%
0.5%
Biotechnology
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States of America
ORLANDO